Literature DB >> 22224589

Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase.

Masahiro Takeyama1, Hironao Wakabayashi, Philip J Fay.   

Abstract

Factor (F) VIII functions as a cofactor in FXase, markedly accelerating the rate of FIXa-catalyzed activation of FX. Earlier work identified a FX-binding site having μM affinity within the COOH-terminal region of the FVIIIa A1 subunit. In the present study, surface plasmon resonance (SPR), ELISA-based binding assays, and chemical cross-linking were employed to assess an interaction between FX and the FVIII light chain (A3C1C2 domains). SPR and ELISA-based assays showed that FVIII LC bound to immobilized FX (K(d) = 165 and 370 nM, respectively). Furthermore, active site-modified activated protein C (DEGR-APC) effectively competed with FX in binding FVIII LC (apparent K(i) = 82.7 nM). Western blotting revealed that the APC-catalyzed cleavage rate at Arg(336) was inhibited by FX in a concentration-dependent manner. A synthetic peptide comprising FVIII residues 2007-2016 representing a portion of an APC-binding site blocked the interaction of FX and FVIII LC (apparent K(i) = 152 μM) and directly bound to FX (K(d) = 7.7 μM) as judged by SPR and chemical cross-linking. Ala-scanning mutagenesis of this sequence revealed that the A3C1C2 subunit derived from FVIII variants Thr2012Ala and Phe2014Ala showed 1.5- and 1.8-fold increases in K(d) for FX, whereas this value using the A3C1C2 subunit from a Thr2012Ala/Leu2013Ala/Phe2014Ala triple mutant was increased >4-fold. FXase formed using this LC triple mutant demonstrated an ~4-fold increase in the K(m) for FX. These results identify a relatively high affinity and functional FX site within the FVIIIa A3C1C2 subunit and show a contribution of residues Thr2012 and Phe2014 to this interaction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22224589      PMCID: PMC3298758          DOI: 10.1021/bi201731p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg336.

Authors:  Mary E Koszelak Rosenblum; Kyla Schmidt; Jan Freas; Maria Mastri; Philip J Fay
Journal:  J Biol Chem       Date:  2002-01-17       Impact factor: 5.157

2.  Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain.

Authors:  Keiji Nogami; Kirsty A Lapan; Qian Zhou; Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2004-02-04       Impact factor: 5.157

3.  Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

Authors:  L O Andersson; N Forsman; K Huang; K Larsen; A Lundin; B Pavlu; H Sandberg; K Sewerin; J Smart
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

Authors:  D Eaton; H Rodriguez; G A Vehar
Journal:  Biochemistry       Date:  1986-01-28       Impact factor: 3.162

5.  The size of human factor VIII heterodimers and the effects produced by thrombin.

Authors:  P J Fay; M T Anderson; S I Chavin; V J Marder
Journal:  Biochim Biophys Acta       Date:  1986-06-23

6.  The binding of activated protein C to factors V and Va.

Authors:  S Krishnaswamy; E B Williams; K G Mann
Journal:  J Biol Chem       Date:  1986-07-25       Impact factor: 5.157

7.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

8.  Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.

Authors:  D L Eaton; W I Wood; D Eaton; P E Hass; P Hollingshead; K Wion; J Mather; R M Lawn; G A Vehar; C Gorman
Journal:  Biochemistry       Date:  1986-12-30       Impact factor: 3.162

9.  Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.

Authors:  H Wakabayashi; M E Koszelak; M Mastri; P J Fay
Journal:  Biochemistry       Date:  2001-08-28       Impact factor: 3.162

10.  Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation.

Authors:  Keiji Nogami; Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2003-02-26       Impact factor: 5.157

View more
  5 in total

Review 1.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

2.  Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.

Authors:  Armando Tripodi; Veena Chantarangkul; Lidia Padovan; Marigrazia Clerici; Erica Scalambrino; Flora Peyvandi
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

3.  Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.

Authors:  Masahiro Takeyama; Hironao Wakabayashi; Philip J Fay
Journal:  Thromb Haemost       Date:  2012-12-06       Impact factor: 5.249

Review 4.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

5.  Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.

Authors:  Takehisa Kitazawa; Keiko Esaki; Tatsuhiko Tachibana; Shinya Ishii; Tetsuhiro Soeda; Atsushi Muto; Yoshiki Kawabe; Tomoyuki Igawa; Hiroyuki Tsunoda; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Thromb Haemost       Date:  2017-04-28       Impact factor: 5.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.